Table 3.
Baseline characteristics of 71 IMN patients for detecting circulating anti-PLA2R antibody and PLA2R expression in different genotypes
| Characteristic | PLA2R Low Risk/HLA Low Risk | PLA2R Low Risk/HLA High Risk | PLA2R High Risk/HLA Low Risk | PLA2R High Risk/HLA High Risk | P Value |
| Patients (n) | 19 | 5 | 21 | 26 | |
| Age (yr) | 44±11 | 54±7 | 52±14 | 48±9 | 0.12 |
| Sex (men/women) | 7/12 | 3/2 | 9/12 | 8/18 | 0.62 |
| Systolic BP (mmHg) | 126±23 | 129±11 | 127±14 | 127±18 | 0.99 |
| Diastolic BP (mmHg) | 79±12 | 80±13 | 80±9 | 81±14 | 0.97 |
| Proteinuria (g/24 h) | 4.04 (0.58, 13.15) | 11.07 (2.81, 19.33) | 4.56 (0.69, 16.49) | 4.09 (0.68, 8.12) | 0.85 |
| Serum albumin (g/L) | 28.07±9.05 | 25.22±8.20 | 25.47±5.33 | 26.27±6.74 | 0.70 |
| Serum creatinine (μmol/L) | 76.46±26.99 | 87.04±28.13 | 66.86±19.02 | 66.82±18.83 | 0.16 |
| Total cholesterol (mmol/L) | 8.65±4.98 | 8.74±2.81 | 7.93±2.36 | 7.12±2.08 | 0.49 |
| Total triglycerides (mmol/L) | 3.34±2.78 | 2.52±1.06 | 3.08±1.62 | 2.20±1.03 | 0.23 |
| Estimated GFR (ml/min per 1.73 m2) | 104.32±37.08 | 89.10±35.95 | 118.81±39.30 | 115.94±26.75 | 0.25 |
| Pathology stage (I/II,III) | 16/3 | 5/0 | 10/11 | 10/16 | <0.001 |
| No immunosuppressive treatment (%) | 14 (74) | 2 (40) | 15 (71) | 19 (73) | 0.86 |
| Anti-PLA2R (%) | 0 (0) | 1 (20) | 16 (76) | 19 (73) | <0.001 |
| Anti-PLA2R in patients without immunosuppressive therapy (%) | 0 (0, 0/14) | 0 (0, 0/2) | 11 (73, 11/15) | 17 (89, 17/19) | <0.001 |
| PLA2R staining in glomeruli (%) | 0/19 (0) | 2/5 (40) | 16/21 (76) | 18/24 (75) | <0.001 |
Data are presented as mean ± SEM or median (interquartile range) unless otherwise indicated. PLA2R1 low risk, individuals with CC in rs35771982, CC in rs3749117, GG in rs4664308 within PLA2R1; PLA2R1 high risk, individuals with GG in rs35771982, TT in rs3749117, AA in rs4664308 within PLA2R1; HLA-DQA1 low risk, individuals with GG in rs2187668 within HLA-DQA1; HLA-DQA1 high risk, individuals with AA or GA in rs2187668 within HLA-DQA1.